Global Cystic Fibrosis Therapeutics Market (2019 to 2026) - CAGR of 9.2% Expected During the Forecast Period - ResearchAndMarkets.com

DUBLIN--()--The "Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026.

Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient's ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a sweat test and recommend additional testing to confirm the diagnosis.

Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market.

Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.

The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled.

Key players

  • Genentech, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Allergan plc.
  • Pharmaxis Ltd.
  • Mylan N.V.

Key findings of the report

  • By drug class, the CFTR segment accounted for the highest market share of 65% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
  • By region, Europe was the major shareholder and accounted for the highest share of 33% in 2018.
  • By route of administration, oral segment is expected to grow at a CAGR of 9.9% during the forecast period.
  • North America is anticipated to grow at the fastest CAGR of 9.8% during the forecast period.

Key Topics Covered:

1. Introduction

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools & Models

2. Executive Summary

2.1. CXO Perspective

3. Market Overview

3.1. Market Definition And Scope

3.2. Porter's Five Forces Analysis

3.3. Top Player Positioning

3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)

3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis

3.4.2. Restraints

3.4.2.1. Low Awareness In Developing Nations

3.4.3. Opportunity

3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics

4. Cystic Fibrosis Therapeutics Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Pancreatic Enzyme Supplements

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Analysis, By Country

4.3. Mucolytics

4.4. Bronchodilators

4.5. Cftr Modulators

5. Cystic Fibrosis Therapeutics Market, By Route Of Administration

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Oral

5.2.1. Market Size And Forecast

5.2.2. Market Analysis, By Country

5.3. Inhale

6. Cystic Fibrosis Therapeutics Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.2.1. Key Trends And Opportunities

6.2.2. North America Market Size And Forecast, By Country

6.2.2.1. U.S. Market Size And Forecast, By Drug Class

6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration

6.2.2.3. Canada Market Size And Forecast, By Drug Class

6.2.2.4. Canada Market Size And Forecast, By Route Of Administration

6.2.2.5. Mexico Market Size And Forecast, By Drug Class

6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration

6.2.3. North America Market Size And Forecast, By Drug Class

6.2.4. North America Market Size And Forecast, By Route Of Administration

6.3. Europe

6.4. Asia-Pacific

6.5. LAMEA

7. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/yxaxkl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900